Novartis gets US approval for delayed MS drug Ruby Khatun Khatun16 Feb 2018 10:00 AM ISTZURICH: Novartis’s Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly...
Another Setback : SC rejects petition by Singh brothers against Daiichi's arbitration award Ruby Khatun Khatun16 Feb 2018 9:50 AM ISTNew Delhi: Another setback has come to Singh brothers as the Supreme Court today rejected their petition for seeking permission to appeal a High Court...
Norwest Venture raises 1.5 billion dollar fund, its largest ever Ruby Khatun Khatun16 Feb 2018 9:45 AM ISTSAN FRANCISCO: Silicon Valley firm Norwest Venture Partners has raised its largest fund to date, a $1.5 billion pool of money, joining a wave of...
AstraZeneca India launches once-daily Xigduo XR tablets for type 2 diabetes Ruby Khatun Khatun15 Feb 2018 3:47 PM ISTAstraZeneca Pharma India Limited (AstraZeneca India) has announced the launch of its innovative anti-diabetic combination once-daily therapy Xigduo®...
Sun Pharma Q3 profit drops 75 percent Ruby Khatun Khatun15 Feb 2018 12:30 PM ISTNew Delhi: Sun Pharmaceutical Industries reported a 75.17 percent decline in its consolidated net profit at Rs 365.39 crore for the December quarter,...
Singh brothers resign from board of Religare Enterprises Ruby Khatun Khatun15 Feb 2018 10:45 AM ISTNew Delhi: Diversified financial services firm Religare Enterprises said Malvinder Mohan Singh and Shivinder Mohan Singh have resigned from the...
Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals Ruby Khatun Khatun15 Feb 2018 10:30 AM ISTKolkata: The Calcutta High Court has set aside the Centres decision to go for strategic sale of century-old Bengal Chemicals and Pharmaceuticals Ltd...
Aster DM Healthcare IPO subscribed 45 percent on day 2 Ruby Khatun Khatun15 Feb 2018 10:15 AM ISTNew Delhi: The initial public offer of Aster DM Healthcare has subscribed 45 percent on the second day of its public issue, according to merchant...
FDA approves Johnson and Johnson prostate cancer treatment Ruby Khatun Khatun15 Feb 2018 9:45 AM ISTThe U.S. Food and Drug Administration approved Johnson and Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but...
Bristol-Myers to pay 1.85 billion dollars in cancer deal with Nektar Ruby Khatun Khatun15 Feb 2018 9:30 AM ISTBristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug,...
Diabetic drugs : Cipla partners with Novartis and Johnson while Alkem partners Dong A Ruby Khatun Khatun14 Feb 2018 1:26 PM ISTMUMBAI: In order to foray into antidiabetic drug market pharma giant Cipla and Mumbai based Alkem Pharma has tied up with multinationals for gliptin...
Govt Revision of Stent prices: Industry woes but Consumers Rejoice Ruby Khatun Khatun13 Feb 2018 2:14 PM ISTNew Delhi: Almost a year after it slashed rates of coronary stents by up to 85 percent, the NPPA on Monday revised the ceiling prices of bare metal...
